1. Home
  2. Analysis
  3. Campath
  4. Herpes-simplex-aggravated

Campath and Herpes simplex aggravated - a phase IV clinical study of FDA data

Summary:

Herpes simplex aggravated is reported as a side effect among people who take Campath (alemtuzumab), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Cyclosporine, and have Bone marrow conditioning regimen.

The phase IV clinical study analyzes which people have Herpes simplex aggravated when taking Campath. It is created by eHealthMe based on reports of 4,897 people who have side effects when taking Campath from the FDA, and is updated regularly.

What is Campath?

Campath has active ingredients of alemtuzumab. eHealthMe is studying from 4,909 Campath users. Check the latest studies of Campath.

What is Herpes simplex aggravated?

Herpes simplex aggravated (serious herpes simplex is a common viral infection) is found to be associated with 704 drugs and 290 conditions by eHealthMe. Check the latest studies of Herpes simplex aggravated.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

4,897 people reported to have side effects when taking Campath.
Among them, 40 people (0.82%) have Herpes simplex aggravated.

Could Campath cause Herpes simplex aggravated?

Among these 40 people:

How long have people been on Campath when they have Herpes simplex aggravated? *

  • < 1 month: 69.23 %
  • 1 - 6 months: 30.77 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Herpes simplex aggravated when taking Campath? *

  • female: 57.14 %
  • male: 42.86 %

What is the age of people who have Herpes simplex aggravated when taking Campath? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 7.69 %
  • 20-29: 3.85 %
  • 30-39: 19.23 %
  • 40-49: 15.38 %
  • 50-59: 34.62 %
  • 60+: 19.23 %

What are other drugs people take besides Campath? *

  1. Cyclosporine: 13 people, 32.50%
  2. Acyclovir: 9 people, 22.50%
  3. Fludara: 8 people, 20.00%
  4. Melphalan: 7 people, 17.50%
  5. Cyclophosphamide: 7 people, 17.50%
  6. Fludarabine Phosphate: 5 people, 12.50%
  7. Fluconazole: 5 people, 12.50%
  8. Mozobil: 5 people, 12.50%
  9. Mycophenolate Mofetil: 5 people, 12.50%
  10. Methylprednisolone: 4 people, 10.00%

What are other side effects people have besides Herpes simplex aggravated? *

  1. Cytomegalovirus Infection: 13 people, 32.50%
  2. Febrile Neutropenia (fever with reduced white blood cells): 9 people, 22.50%
  3. Sepsis (a severe blood infection that can lead to organ failure and death): 8 people, 20.00%
  4. Herpes Zoster: 8 people, 20.00%
  5. Respiratory Syncytial Virus Infection (viral disease of respiratory system): 8 people, 20.00%
  6. Mucosal Inflammation (infection of mucous membrane): 8 people, 20.00%
  7. Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 6 people, 15.00%
  8. Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 6 people, 15.00%
  9. Adenovirus Infection: 6 people, 15.00%
  10. The Flu (the flu is caused by an influenza virus): 6 people, 15.00%

What are the existing conditions these people have? *

  1. Bone Marrow Conditioning Regimen: 12 people, 30.00%
  2. Haematopoietic Stem Cell Mobilisation: 4 people, 10.00%
  3. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 4 people, 10.00%
  4. Lymphoma (cancer that begins in immune system cells): 3 people, 7.50%
  5. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 2 people, 5.00%
  6. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 2 people, 5.00%
  7. Transplant Rejection (a transplant material is not worked): 1 person, 2.50%
  8. T-Cell Depletion (less supply of t-cell by bone marrow): 1 person, 2.50%
  9. Peripheral T-Cell Lymphoma Unspecified (peripheral t-cell cancer unspecified): 1 person, 2.50%
  10. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Campath and have Herpes simplex aggravated?

- Check whether Herpes simplex aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Campath:

Herpes simplex aggravated treatments and more:

How severe was Herpes simplex aggravated and when was it recovered:

Expand to all the drugs that have ingredients of alemtuzumab:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Campath:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Herpes simplex aggravated:

Browse all the conditions that are associated with Herpes simplex aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on alemtuzumab (the active ingredients of Campath) and Campath (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.